Gliadel for pituitary adenomas and craniopharyngiomas

Edward R. Laws, Angel M. Morris, Nicholas Maartens, Henry Brem, Kyle D. Weaver, Manfred Westphal, Kalmon D. Post, Wesley King, Victor A. Levin

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


OBJECTIVE: We developed a protocol for a clinical trial of postresection implantation of Gliadel wafers in patients with aggressive, relentlessly recurring pituitary adenomas and craniopharyngiomas. METHODS: Ten patients, nine with pituitary adenomas and one with a craniopharyngioma, underwent implantation of from two to eight Gliadel wafers. RESULTS: No obvious adverse reactions occurred. Death as a result of disease progression occurred in two patients with malignant adenomas. One patient died as a result of a stroke after undergoing five surgical procedures and prior radiotherapy. The seven living patients have been followed for 5 to 27 months (mean follow-up, 19 mo). Four patients have been free of recurrent or residual tumor, two have stable residual disease, and one has experienced tumor progression. CONCLUSION: The results of this study suggest a role for Gliadel implantation in patients with recurring aggressive pituitary adenomas and craniopharyngiomas.

Original languageEnglish (US)
Pages (from-to)255-260
Number of pages6
Issue number2
StatePublished - Aug 1 2003


  • Carmustine
  • Craniopharyngioma
  • Gliadel
  • Pituitary adenoma
  • Polymer

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Gliadel for pituitary adenomas and craniopharyngiomas'. Together they form a unique fingerprint.

Cite this